Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 3,459 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matching Oral Placebo Clear all
Completed Phase 2 Interventional Results available

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

NCT02215616
View directory record Official record
Conditions
Huntington's Disease
Interventions
Laquinimod, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
21 Years to 55 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 18, 2026, 8:48 AM EDT
Not yet recruiting Phase 4 Interventional

Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Sinusitis)

NCT07732699
View directory record Official record
Conditions
ACUTE SINUSITIS, Sinusitis
Interventions
Amoxicillin, Amoxi Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
2 Years to 12 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Terminated Phase 2 Interventional Results available

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02787304
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Coronado, California • Fresno, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers

NCT01282684
View directory record Official record
Conditions
Healthy
Interventions
PLX5622, Placebo
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 3 Interventional Results available

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

NCT00863655
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Exemestane, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
63
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 18, 2026, 8:48 AM EDT
Active, not recruiting Phase 3 Interventional

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

NCT07007793
View directory record Official record
Conditions
Primary Hyperaldosteronism
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 2 Interventional Results available

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

NCT02254421
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Presatovir, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Duarte, California • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 18, 2026, 8:48 AM EDT
Active, not recruiting Early Phase 1 Interventional

Autonomic Determinants of POTS - Pilot 2

NCT04140721
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Placebo oral tablet, Moxonidine Pill
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 2 Interventional Results available

Tafenoquine in Patients With Mild to Moderate COVID-19

NCT04533347
View directory record Official record
Conditions
COVID 19 Disease
Interventions
Tafenoquine Oral Tablet, Placebo
Drug
Lead sponsor
60 Degrees Pharmaceuticals LLC
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Miami, Florida • Elkhorn, Nebraska • Morgantown, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 18, 2026, 8:48 AM EDT
Recruiting Phase 2 Interventional

Trial of Diphenhydramine for Sleep in Children With Autism

NCT05501678
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Diphenhydramine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Active, not recruiting Not applicable Interventional

Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity

NCT07792616
View directory record Official record
Conditions
Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injuries, Spasticity, Spasm, Muscle Spasticity, Muscle Hypertonia, Muscle Spasm
Interventions
Transcutaneous spinal stimulation at 30 Hz, Transcutaneous spinal stimulation at 75 Hz, Tizanidine, Baclofen, Placebo
Other · Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT03584516
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Itacitinib, Placebo, Methylprednisolone, Prednisone
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 18, 2026, 8:48 AM EDT
Active, not recruiting Not applicable Interventional

Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis:

NCT05505552
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Vitamin K, Placebo
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 3 Interventional

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

NCT06588738
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Envudeucitinib, Placebo, Apremilast
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease

NCT00325728
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
55 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
72
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients

NCT00734630
View directory record Official record
Conditions
Hypertension
Interventions
nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
75
States / cities
Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 18, 2026, 8:48 AM EDT
Active, not recruiting Early Phase 1 Interventional

Targeting Drug Memories With Methylphenidate

NCT05978167
View directory record Official record
Conditions
Substance Use Disorder, Cocaine Use Disorder
Interventions
Methylphenidate, Memory reconsolidation, Placebo
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
26 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 3 Interventional

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

NCT00143663
View directory record Official record
Conditions
Dyslipidemia
Interventions
Lapaquistat Acetate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
47
States / cities
Northport, Alabama • Mesa, Arizona • Chula Vista, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 18, 2026, 8:48 AM EDT
Terminated Not applicable Interventional

The Effect of Lysulin on Glycemic Control and Advanced Glycation

NCT04234581
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lysulin
Dietary Supplement
Lead sponsor
Juraj Koska
Federal
Eligibility
21 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

NCT02272634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
YPL-001 80 mg, YPL-001 160 mg, Placebo
Drug
Lead sponsor
Yungjin Pharm. Co., Ltd.
Industry
Eligibility
30 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

NCT01999114
View directory record Official record
Conditions
ECG Effects
Interventions
Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

NCT01735630
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ELND005, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

NCT04978298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Rasigiline, Phenelzine, Ozanimod
Other · Drug
Lead sponsor
Celgene
Industry
Eligibility
25 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

NCT05518734
View directory record Official record
Conditions
Pain
Interventions
VX-708, Itraconazole, Midazolam, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 18, 2026, 8:48 AM EDT